Network Audit 2011-12 Patients with Confirmed Small Cell Lung Cancer Who Did Not Receive Chemotherapy Dr D N Leitch On Behalf of Lung Cancer NSSG NECN.

Slides:



Advertisements
Similar presentations
National Prostate Cancer Audit Julie Nossiter, Project Manager Clinical Effectiveness Unit – Royal College of Surgeons.
Advertisements

National Prostate Cancer Audit Heather Payne, NPCA Oncological Clinical Lead Consultant Clinical Oncologist, UCL.
Cancer of Unknown Primary Dr Chris Jones Consultant Medical Oncologist North of England Cancer Network Annual Conference 20 September 2013.
ATLAS Steering Committee: 24 September 2005 Steering Committee meeting, 24 th September 2005 University of Oxford Examination Schools.
National Prostate Cancer Audit: Review of the Organisational Audit Dr Ajay Aggarwal Oncology Coordinator NPCA Honorary.
National Oesophago–Gastric Cancer Audit Comparing local and national figures.
Door to Needle Neutropenic Sepsis Audit (Macmillan Chemotherapy Unit ) May 11– October 11 Baleseng Nkolobe NWLH NHS Trust Chemotherapy Lead Nurse/Matron.
Resection rate for patients with tissue confirmation of NSCLC ( :England) First seen in centre with thoracic surgery? Number With a tissue diagnosis.
NECN S/C Herceptin Reactions October 2014 Wendy Anderson Macmillan Nurse Consultant Chemotherapy STNHSFT Melanie Robertson Nurse Consultant Oncology CHS.
Giving Induction Radiation in Addition to Chemotherapy Is Not Associated with Improved Survival of NSCLC Patients with Operable Mediastinal Nodal Disease.
Impact of Cancer Diagnosis and Chemotherapy on Mammography Use Xinhua Yu, M.B., Ph.D. A. Marshall McBean, M.D., M.Sc. Beth A. Virnig, Ph.D., M.P.H Division.
The All Breast Cancer Report was published in October breastscreen/research.html#breast- cancer-report.
Audit of EGFR mutation testing in patients with proven Non-Small Cell Lung Cancer On behalf of the North of England Cancer Network Lung NSSG Dr Naomi Chamberlin,
NECN Lung NSSG April 2012 Managing Solitary Brain Metastases from NSCLC Dr Paula Mulvenna Consultant Clinical Oncologist Northern Centre for Cancer Care.
Experience and Outcomes with Hypofractionated Concurrent Chemoradiation for Stage III NSCLC at NCCC Gregory Webb Medical Student.
Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal canal. Eng C1, Rogers J2, Chang GJ3, You N3, Das P4, Rodriguez-Bigas.
National Oesophago–Gastric Cancer Audit Key Findings from 2014 Annual Report and Progress Report Georgina Chadwick Clinical Research Fellow.
Dr Poonam Valand, Foundation Year Two Dr Anjan Dhar, Consultant Gastroenterologist COUNTY DURHAM AND DARLINGTON NHS FOUNDATION TRUST Early gastric cancer.
Background  Reports of long-term survivors (≥5 years) of locally advanced esophageal cancer (LAEC) have focused mainly on HRQL or GI symptoms  Only.
The treatment of metastatic squamous cell carcinoma (SCCA) of the anal canal: A single institution experience P. Pathak, B. King, A. Ohinata, P. Das, C.H.
WALES BREAST CANCER CLINICAL AUDIT (WBCCA) MDT DATA FOR PATIENTS DIAGNOSED in 2009, 2010 and 2011 CTUHB (Royal Glamorgan and Price Charles Hospitals) MDT.
Cmab might have therapeutic benefit in Japanese patients with KRAS p.G13D mutant colorectal cancer. Limitations of this study are its retrospective design.
NECN Colorectal NSSG Audit of Waiting Times for Lower GI Cancer Patients in NECN April 2010 – March 2011.
LUCADA Jacqueline Brown Cancer Services Manager North Tees & Hartlepool Trust.
Cancer Information Framework Initial feedback on NWCN LUCADA submission 2006 data Wednesday 20 th February, 2008 Linda Roberts, Cancer Information Specialist,
National Oesophago–Gastric Cancer Audit  This slide set is designed to ◦Summarise the main audit findings for presentation at local MDT meetings.
National Cancer Intelligence Network Outcome and the effect of age in 1318 patients with synovial sarcoma: Report from the National Cancer Intelligence.
Patterns of Care and Prognosis of Retroperitoneal Sarcomas in the Primary and Advanced Settings A Large Multicentric Retrospective Analysis from the French.
Provisional MUO Audit Tania Tillett Medical Oncologist RUH.
How clinicians use data to make an impact on clinical outcomes Andrew Brodbelt Consultant Neurosurgeon and Clinical Director of Neurosurgery, The Walton.
Two-week wait referrals for malignant melanoma: A clinical audit carried out across four UK Cancer Networks South West Cancer Intelligence Service
Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer in the Elderly: A Population-Based Study in Ontario, Canada JOURNAL OF CLINICAL ONCOLOGY, VOLUME 30.
Sex-specific trends in lung cancer incidence and survival : a population study of cases 호흡기 내과 R3 조주희 Thorax 2011;66: Camilla M T Sagerup,
How clinicians use data to make an impact on clinical outcomes Dr Mick Peake Clinical Lead, National Cancer Intelligence Network Consultant & Senior Lecturer.
[Name of Presenter] [Details of patient e.g. initials, hospital number etc.] [Date of meeting]
How Functional is a Functional Neck Dissection ? Photo by Christine Hodgson Barry Scott, Senior 1 Physiotherapist Aintree Hospitals NHS Trust Quality of.
MESOTHELIOMA PROGNOSIS A mesothelioma prognosis reflects how certain factors may impact your life expectancy and affect your chances of recovery. The average.
Introduction Data Statistical Methods Table 1: Prevalence of Prior Hip Fracture and Incidence of New Hip Fractures and Fractures of Any Type.
Patient characteristics Ulcer characteristics
Oesophago–Gastric Cancer Audit
Accelerated radical radiotherapy for Non Small Cell Lung Cancer: Single centre audit outcome of two fractionations in the treatment of the elderly patients.
Brain imaging prior to lung cancer resection
Oesophago–Gastric Cancer
Delivery of systemic therapy in Gloucestershire for NSCLC
TEXILA AMERICAN UNIVERSITY
National Oesophago–Gastric Cancer Audit 2015.
Stage I Non Small Cell Lung Cancer (NSCLC): single centre comparison of outcome by treatment with surgery, conventional radiotherapy and stereotactic ablative.
1 Maidstone and Tunbridge Wells NHS Trust (Kent Oncology Centre)
HANA Audit Update for SSG
Syndrome of Inappropriate Antidiuretic Hormone (SIADH) in Lung Cancer 12 months experience from a Cancer Unit Bulusu V R, Jessop S, Jeffs Y P, Thomas.
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
Curative treatment rates for patients diagnosed with
Prognosis of younger patients in non-small cell lung cancer
Oesophago–Gastric Cancer
930P - A retrospective single institution study evaluating clinical outcome and prognostic markers for endometrial and ovarian carcinosarcomas (CS) U.Asghar1,
Oesophago–Gastric Cancer
Pathway for patients with suspected Breast Cancer
National Lung Cancer Audit
Hannah Marder Cancer Manager UH Bristol
Results from the first National Lung Cancer Organisational Audit.
Treatment breakdown for SCLC cancers
Pathway for patients with suspected colorectal cancer
National Oesophago-Gastric Cancer Audit 2018 Annual Report: Slide set
2018 National Mesothelioma Audit
Joshua E. Rosen, BASc, Michelle C
Experience of Tyrosine-Kinase Inhibitors (TKI) for 1st line NSCLC
Pathway for patients with suspected HPB Cancer Inter Provider Transfer
Pathway for patients with suspected Breast Cancer
Trends in survival from metastatic lung cancer in California,
Presentation transcript:

Network Audit Patients with Confirmed Small Cell Lung Cancer Who Did Not Receive Chemotherapy Dr D N Leitch On Behalf of Lung Cancer NSSG NECN

Introduction National Lung Cancer Audit - “Chemotherapy rates for small cell lung cancer below the England and Wales average of 65 per cent should be reviewed” Important clinical line of enquiry used in Peer Review Required consideration in annual self assessment report If gone as far as confirming diagnosis – Why no treatment?

NLCA Results 2010 Patients Code Actual number Number of patients small cell lung cancer % small cell receiving chemotherapy RE % RLN % RNL % RR % RTD % RTF % RTR % RVW % RXP % N36 Total2, % LUCADA Total 32,3473, %

Methods Retrospective case note audit All Trusts participated Patients diagnosed with lung cancer during 12 months to Results match the current 2011 National Lung Cancer Audit (NLCA) report for 2010 patients Results submitted to NECN, collated and analysed

Number of Cases in Audit vs Expected Trust (N36) Number of Cases Small Cell Small Cell Chemotherapy Rate Expected Number in Audit Number in Audit RE %6 RLN3369.7%108 (80%) RNL3452.9%169 (56%) RR %87 (88%) RTD4374.4%119 (82%) RTF3857.9%168 (50%) RTR4759.6%1915 (79%) RVW2965.5%107 (70%) RXP4562.2%1717 (100%) National %11380 (71%) NECN3, %2334

Results Patient characteristics Investigation Treatment

Median Age = 74 years (IQR 66-90)

CT Performed and MDT Discussion

Survivors >100 days vs All Patients >100 days survivalAll Median Age (IQR)78.5 (70-90)74.0 (66-90) M:F5:11 (45%)30:49 (38%) Co-morbidity14:2 (87.5%)57/80 (71%) Stage 3b,412/16 (75%)69/80 (75%) Performance Status 3,48/16 (50%)51/80 (64%) Chemotherapy discussed14/15 (88%)62/77 (81%) Chemotherapy refused7/10 (70%)20/57 (35%) Seen by Oncologist10/16 (63%)47/79 (60%) Treated with radiotherapy10/16 (63%)22/47 (46%)

Conclusions NLCA data collection is improving each year – Good quality comprehensive data important Process of audit is most valuable in reflecting on current practice – Surgical resection, histological confirmation, SCLC Chemotherapy Actual figures in audit are not the figures reported in NLCA – pre- upload review may significantly improve NLCA data values Almost all patients discussed at MDT meetings Almost all patients had a CT

Conclusions Median age was 74 years Too many (44%) presented as emergencies vs 41% as 2WR Too many had poor WHO PS – 64% WHO = 3 or 4 Significant Co-morbidity 71% 81% Chemotherapy discussed with patient 25% patients refused chemotherapy 60% seen by oncologist If no chemotherapy – about 25% had radiotherapy Longer survivors – older, more co-morbidity, better WHO-PS more likely to refuse chemotherapy

Actions Review data before uploaded if possible Ensure older patients with co-morbidity and better WHO – PS have full discussion, offer of chemotherapy and review with oncology - Other suggestions?